The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
CONCLUSIONS: HLA-C*06:02 but not age at psoriasis onset is a predictive biomarker for biologic survival in psoriasis patients. Findings from this large cohort provide further, important information to aid clinicians using biologic therapies to manage psoriasis patients.PMID:38051972 | DOI:10.1093/bjd/ljad481 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - December 5, 2023 Category: Dermatology Authors: Oras A Alabas Kayleigh J Mason Zenas Z N Yiu Richard B Warren Nick Dand Jonathan N Barker Catherine H Smith Christopher E M Grif fiths BADBIR study groups BSTOP study groups Source Type: research
Drug-induced tumoral disease: A global pharmacovigilance database analysis
DISCUSSION: Our results show that the main pharmacological mechanisms are associated with ranitidine (link with levels of N-nitrosodimethylamine in ranitidine-based drugs), gene-activating drugs (pioglitazone: link with agonist effects on PPAR-γ gene activation), various pharmacological families with immunosuppressive effects (protein kinase inhibitors, immunomodulators, azathioprine, etc.), certain types of protein kinase inhibitors whose oncogenic mechanisms remain unclear (regorafenib, sorafenib, imatinib, ibrutinib, etc.), and hormone antagonists (tamoxifen, letrozole). Special monitoring of patients exposed to these ...
Source: Therapie - December 2, 2023 Category: Psychiatry & Psychology Authors: Yoann Zelmat Fabien Despas Source Type: research
Drug-induced tumoral disease: A global pharmacovigilance database analysis
DISCUSSION: Our results show that the main pharmacological mechanisms are associated with ranitidine (link with levels of N-nitrosodimethylamine in ranitidine-based drugs), gene-activating drugs (pioglitazone: link with agonist effects on PPAR-γ gene activation), various pharmacological families with immunosuppressive effects (protein kinase inhibitors, immunomodulators, azathioprine, etc.), certain types of protein kinase inhibitors whose oncogenic mechanisms remain unclear (regorafenib, sorafenib, imatinib, ibrutinib, etc.), and hormone antagonists (tamoxifen, letrozole). Special monitoring of patients exposed to these ...
Source: Therapie - December 2, 2023 Category: Psychiatry & Psychology Authors: Yoann Zelmat Fabien Despas Source Type: research
Drug-induced tumoral disease: A global pharmacovigilance database analysis
DISCUSSION: Our results show that the main pharmacological mechanisms are associated with ranitidine (link with levels of N-nitrosodimethylamine in ranitidine-based drugs), gene-activating drugs (pioglitazone: link with agonist effects on PPAR-γ gene activation), various pharmacological families with immunosuppressive effects (protein kinase inhibitors, immunomodulators, azathioprine, etc.), certain types of protein kinase inhibitors whose oncogenic mechanisms remain unclear (regorafenib, sorafenib, imatinib, ibrutinib, etc.), and hormone antagonists (tamoxifen, letrozole). Special monitoring of patients exposed to these ...
Source: Therapie - December 2, 2023 Category: Psychiatry & Psychology Authors: Yoann Zelmat Fabien Despas Source Type: research
Drug-induced tumoral disease: A global pharmacovigilance database analysis
DISCUSSION: Our results show that the main pharmacological mechanisms are associated with ranitidine (link with levels of N-nitrosodimethylamine in ranitidine-based drugs), gene-activating drugs (pioglitazone: link with agonist effects on PPAR-γ gene activation), various pharmacological families with immunosuppressive effects (protein kinase inhibitors, immunomodulators, azathioprine, etc.), certain types of protein kinase inhibitors whose oncogenic mechanisms remain unclear (regorafenib, sorafenib, imatinib, ibrutinib, etc.), and hormone antagonists (tamoxifen, letrozole). Special monitoring of patients exposed to these ...
Source: Therapie - December 2, 2023 Category: Psychiatry & Psychology Authors: Yoann Zelmat Fabien Despas Source Type: research
Nail lichen planus treatment safety
Expert Opin Drug Saf. 2023 Nov 28. doi: 10.1080/14740338.2023.2288902. Online ahead of print.ABSTRACTTopical therapies for nail lichen planus (clobetasol propionate, topical tacrolimus, bath-PUVA), intralesional treatment (triamcinolone), and systemic treatment (corticosteroids, retinoids, small molecule inhibitors (jak/stat inhibitors), TNF-alpha inhibitors (etanercept), systemic immunomodulators (oral calcineurin inhibitors, mycophenolate mophetil), and antimalarials (chloroquine), each with unique safety profiles and considerations. Herein, we discuss common and uncommon adverse events, as well as utilization for specia...
Source: Expert Opinion on Drug Safety - November 28, 2023 Category: Drugs & Pharmacology Authors: Eden N Axler Shari R Lipner Source Type: research
Nail lichen planus treatment safety
Expert Opin Drug Saf. 2023 Nov 28:1-12. doi: 10.1080/14740338.2023.2288902. Online ahead of print.ABSTRACTTopical therapies for nail lichen planus (clobetasol propionate, topical tacrolimus, bath-PUVA), intralesional treatment (triamcinolone), and systemic treatment (corticosteroids, retinoids, small molecule inhibitors (jak/stat inhibitors)), TNF-alpha inhibitors (etanercept), systemic immunomodulators (oral calcineurin inhibitors, mycophenolate mophetil), and antimalarials (chloroquine), each with unique safety profiles and considerations. Herein, we discuss common and uncommon adverse events, as well as utilization for ...
Source: Expert Opinion on Drug Safety - November 28, 2023 Category: Drugs & Pharmacology Authors: Eden N Axler Shari R Lipner Source Type: research
ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy
CONCLUSIONS: This multicentre retrospective observational study of bDMARDs used in the treatment of RA showed that, for all the drugs studied, there was no problem with adherence to treatment but rather a difficulty in maintaining treatment with the same drug over time.PMID:37994874 | DOI:10.1080/03007995.2023.2287600 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - November 23, 2023 Category: Research Authors: Fiorenzo Santoleri Ruggero Lasala Paolo Abrate Laura Pestrin Enrico Pasut Germana Modesti Felice Musicco Chiara Fulgenzio Eva Zuzolo Gabriella Pieri Martina Roperti Pietro Gazzola Marco Gambera Isabella Martignoni Valentina Montresor Francesco De Vita Fra Source Type: research
Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Case Report and Literature Review
DISCUSSION: This literature review highlights how SJS/TEN may present differently in patients on immune checkpoint inhibitors. Treatments in these cases may vary from those with classic SJS/TEN. Specifically, etanercept given days late into the disease course is effective in speeding re-epithelialization and tapering of already given corticosteroids in classic SJS/TEN. J Drugs Dermatol. 2023;22(11):e24-e28 doi:10.36849/JDD.6999e.PMID:37943271 | DOI:10.36849/JDD.6999 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - November 9, 2023 Category: Dermatology Authors: Shannon Meledathu Michael Gordon Mason Thornton Robin Ashinoff Source Type: research
